Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pituitary tumor cells in Cushing’s syndrome found to express large amounts of protein receptor

29.10.2002


Treatment with a common diabetes drug effectively shrank these tumors in mice



While most cases of a hormonal disorder called Cushing’s Syndrome are caused by non-cancerous pituitary tumors that secrete too much of a particular hormone resulting in high cortisol levels, the disorder can ultimately lead to an early death for many patients whose tumors cannot be removed surgically.

Now, researchers at Cedars-Sinai Medical Center have found that pituitary tumors express an abundance of a specific protein receptor and report that treatment with a common diabetes drug was effective in shrinking tumor size and reducing hormone production in Cushing’s pituitary tumors in mice. The findings, reported in the November issue of the journal, Nature Medicine, may lead to a new way to treat patients who have Cushing’s Syndrome.


"Now that we know that this protein receptor plays a role in the pituitary tumors that cause Cushing’s syndrome, we may have found a drug that can effectively treat this disease," said Dr. Anthony Heaney, lead author of the study and Assistant Professor and Medical Director of the Neuroendocrine Tumor Center at Cedars-Sinai Medical Center. "We will soon begin a clinical trial to test the effectiveness of this antidiabetic drug in patients with Cushing’s syndrome who have pituitary tumors."

The most common type of Cushing’s syndrome is caused by prolonged high-level exposure of a hormone called ACTH (adrenocorticotropin), which is secreted in excess by tumors of the pituitary gland, situated at the base of the brain and, which controls growth, metabolism and reproduction. Although the disorder is rare, it affects more women than men by a ratio of 5:1. Symptoms include weight gain with rounding of the face; increased fat in the neck; thinning skin; excess hair growth on the face neck, chest abdomen and thighs; muscle weakness and bone loss (osteoporosis); high blood sugar; diabetes; and high blood pressure. These effects are caused by high levels of adrenal steroids, or cortisol. The disorder is commonly treated with surgery to remove the tumor, but tumors are not always completely removed, either because they are too small to detect or have spread to parts of the brain that cannot be accessed via surgical procedures. Further, even if the tumor is successfully removed initially, about 50 percent of patients’ experience a recurrence sometime after surgery.

The protein receptor, called PPAR-gamma (peroxisome proliferator activating receptor), is a member of the steroid family and functions to regulate other genes involved in growth and metabolism. For example, the protein plays a role in the body’s ability to respond to insulin, which lowers blood sugar. In fat cells, PPAR-gamma regulates sugar metabolism.

In view of the relationship between excess steroid hormones and obesity, the investigators first examined normal human pituitary tissue to determine which pituitary cells expressed PPAR-gamma. Their analysis revealed that PPAR-gamma was present selectively on normal ACTH-secreting pituitary cells, leading them to examine tumor specimens that secreted too much ACTH. In this analysis, they evaluated six ACTH-secreting pituitary tumors that had been surgically removed. They found that PPAR-gamma was abundantly expressed in all six tumors, as compared to modest expression in the normal pituitary tissue samples.

"The over-expression of this receptor on pituitary tumor cells indicates that PPAR-gamma may play a major role in the causation of Cushing’s syndrome," said Dr. Shlomo Melmed, senior author of the study and Sr. Vice President of Academic Affairs and Professor and Director of the Burns and Allen Research Institute at Cedars-Sinai Medical Center.

Based on these findings, the investigators tested whether pituitary tumor cells would respond to drugs called thiazolidinediones (TZDs), which are commonly used in the treatment of diabetes and work by activating gamma. To do this, they first treated pituitary tumor cells with two different types of TZD drugs called troglitazone or rosiglitazone. They found that both drugs caused pituitary tumor cells to die, and inhibited secretion of ACTH hormone from the tumor cells.

Given that the TZD’s were effective to induce tumor-cell death and slow the secretion of ACTH in cell cultures, the investigators subsequently tested the drugs in mice with ACTH-secreting pituitary tumor cells, which were then randomly selected to receive food containing rosiglitazone or normal food. After four weeks, the investigators found that four of the five untreated mice developed large, visible pituitary tumors, and the typical Cushing’s features of a "moon shaped" face and large neck. In comparison, only one of the five rosiglitazone treated mice developed a small pituitary tumor. The investigators also found that ACTH and other steroid hormones were considerably lower in the treated mice as compared to those not receiving treatment.

"These results indicate that TZDs may be effective in slowing tumor growth in humans," said Dr. Heaney.



Cedars-Sinai Medical Center is one of the largest non-profit academic medical centers in the Western United States. For the fifth straight two-year period, Cedars-Sinai has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthrough in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

Kelli Stauning | Cedars-Sinai Medical Center
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>